Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Evaluation of the effects of nateglinide on postprandial glycemia in patients with type 2 diabetes mellitus: a multicenter, multinational, non-randomized, non-controlled Latin American study.

Islas-Andrade S, Revilla-Monsalve MC, Martínez de Hurtado E, Chacín LF, Caminos QR, Yupanqui H, López G, de la Torre W; Latin American Study Group.

Pharmacology. 2003 Jun;68(2):89-95.

PMID:
12711836
2.

Evaluation of a new insulinotropic agent by using an innovative technology: efficacy and safety of nateglinide determined by continuous glucose monitoring.

Abrahamian H, Francesconi M, Loiskandl A, Dzien A, Prager R, Weitgasser R.

Diabetes Technol Ther. 2004 Feb;6(1):31-7.

PMID:
15000767
3.

Efficacy and safety of nateglinide in type 2 diabetic patients with modest fasting hyperglycemia.

Saloranta C, Hershon K, Ball M, Dickinson S, Holmes D.

J Clin Endocrinol Metab. 2002 Sep;87(9):4171-6.

PMID:
12213867
4.

Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin.

Raskin P, Klaff L, McGill J, South SA, Hollander P, Khutoryansky N, Hale PM; Repaglinide vs. Nateglinide Metformin Combination Study Group.

Diabetes Care. 2003 Jul;26(7):2063-8. Erratum in: Diabetes Care. 2003 Sep;26(9):2708.

PMID:
12832314
5.

Repaglinide versus nateglinide monotherapy: a randomized, multicenter study.

Rosenstock J, Hassman DR, Madder RD, Brazinsky SA, Farrell J, Khutoryansky N, Hale PM; Repaglinide Versus Nateglinide Comparison Study Group.

Diabetes Care. 2004 Jun;27(6):1265-70.

PMID:
15161773
6.
7.

Nateglinide and acarbose are comparably effective reducers of postprandial glycemic excursions in chinese antihyperglycemic agent-naive subjects with type 2 diabetes.

Zhou J, Li H, Zhang X, Peng Y, Mo Y, Bao Y, Jia W.

Diabetes Technol Ther. 2013 Jun;15(6):481-8. doi: 10.1089/dia.2013.0046. Epub 2013 Apr 30.

8.

Importance of early insulin secretion: comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes.

Hollander PA, Schwartz SL, Gatlin MR, Haas SJ, Zheng H, Foley JE, Dunning BE.

Diabetes Care. 2001 Jun;24(6):983-8.

PMID:
11375357
9.

[Clinical evaluation of efficacy and safety of nateglinide in the treatment of type 2 diabetes].

Li YX, Ding GX, Li QF, Chen L, Hu GL, Ji QH, Wang SJ, Guo Y, Luo R, Hou WK, Wang PN, Zhang NY, Zhang YP, Wang H.

Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2008 Apr;30(2):211-3. Chinese.

10.

Safety and efficacy of nateglinide/metformin combination therapy in the treatment of type 2 diabetes.

Israel MK, Istvan E, Baron MA.

Vasc Health Risk Manag. 2008;4(6):1167-78. Review.

11.
12.

Addition of nateglinide to rosiglitazone monotherapy suppresses mealtime hyperglycemia and improves overall glycemic control.

Fonseca V, Grunberger G, Gupta S, Shen S, Foley JE.

Diabetes Care. 2003 Jun;26(6):1685-90.

PMID:
12766094
13.

Effects of nateglinide and glibenclamide on postprandial lipid and glucose metabolism in type 2 diabetes.

Vakkilainen J, Mero N, Schweizer A, Foley JE, Taskinen MR.

Diabetes Metab Res Rev. 2002 Nov-Dec;18(6):484-90.

PMID:
12469362
14.

Targeting postprandial hyperglycemia: a comparative study of insulinotropic agents in type 2 diabetes.

Carroll MF, Gutierrez A, Castro M, Tsewang D, Schade DS.

J Clin Endocrinol Metab. 2003 Nov;88(11):5248-54.

PMID:
14602757
16.

Acute nateglinide administration in subjects with type 2 diabetes: effects on postprandial metabolism, coagulation, and fibrinolysis.

Tentolouris N, Boutati E, Karambakalis N, Perrea D, Tselepis AD, Tsoukala C, Kyriaki D, Lourida E, Anastasopoulou I, Karafoullidou A, Raptis SA, Katsilambros N.

Nutr Metab Cardiovasc Dis. 2005 Feb;15(1):6-12. Erratum in: Nutr Metab Cardiovasc Dis. 2006 Jan;16(1):81. Perea, D [corrected to Perrea, D].

PMID:
15871845
17.

Synergistic effects of nateglinide and meal administration on insulin secretion in patients with type 2 diabetes mellitus.

Keilson L, Mather S, Walter YH, Subramanian S, McLeod JF.

J Clin Endocrinol Metab. 2000 Mar;85(3):1081-6.

PMID:
10720043
18.

Nateglinide improves postprandial hyperglycemia and insulin secretion in renal transplant recipients.

Voytovich MH, Haukereid C, Hjelmesaeth J, Hartmann A, Løvik A, Jenssen T.

Clin Transplant. 2007 Mar-Apr;21(2):246-51.

PMID:
17425753
19.
20.

Beneficial effects of nateglinide on insulin resistance in type 2 diabetes.

Hazama Y, Matsuhisa M, Ohtoshi K, Gorogawa S, Kato K, Kawamori D, Yoshiuchi K, Nakamura Y, Shiraiwa T, Kaneto H, Yamasaki Y, Hori M.

Diabetes Res Clin Pract. 2006 Mar;71(3):251-5. Epub 2005 Oct 7.

PMID:
16214255

Supplemental Content

Support Center